Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- Dovato (dolutegravir/lamivudine), the once-daily, single-pill, 2-drug regimen for the treatment of HIV-1 infection, granted marketing approval by Japan Ministry of Health, Labour and Welfare
- ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
- Deborah Waterhouse, CEO of ViiV Healthcare, to join GSK Corporate Executive Team (CET)
Tweets from GSK
-
GSK @GSK
We had a great time at #JPMHC20 this week, talking about our long-term priorities, oncology research and patient-driven science. Go #BehindTheScience to find out more gsk.to/361USS3
about 20 hours ago
-
GSK @GSK
We’re proud our Ware Manufacturing site is joining @wef ‘s Global Lighthouse Network as one of 44 factories showing leadership in the Fourth Industrial Revolution. Find out what we’re doing to drive operational and environmental impact: gsk.to/362fr0C twitter.com/wef/status/121…
about 1 day ago
-
GSK @GSK
Thanks to @jimcramer for the opportunity to talk about our key priorities for 2020 #JPMHC20 twitter.com/MadMoneyOnCNBC…
about 1 day ago
